| 2,5-Dimethoxy-4-ethylamphetamine | Remoxipride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. | Experimental, Illicit |
| 3,4-Methylenedioxyamphetamine | Remoxipride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine. | Experimental, Illicit |
| 3,4-Methylenedioxymethamphetamine | Remoxipride may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine. | Experimental, Illicit |
| 4-Bromo-2,5-dimethoxyamphetamine | Remoxipride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine. | Experimental, Illicit |
| 7-Nitroindazole | The risk or severity of adverse effects can be increased when Remoxipride is combined with 7-Nitroindazole. | Experimental |
| Abiraterone | The serum concentration of Remoxipride can be increased when it is combined with Abiraterone. | Approved |
| Acepromazine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Acepromazine. | Approved, Vet Approved |
| Aceprometazine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Aceprometazine. | Approved |
| Adipiplon | The risk or severity of adverse effects can be increased when Remoxipride is combined with adipiplon. | Investigational |
| Agomelatine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Agomelatine. | Approved, Investigational |
| Alfaxalone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Alfaxalone. | Vet Approved |
| Alfentanil | The risk or severity of adverse effects can be increased when Remoxipride is combined with Alfentanil. | Approved, Illicit |
| Allopregnanolone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Sage 547. | Investigational |
| Almotriptan | The risk or severity of adverse effects can be increased when Almotriptan is combined with Remoxipride. | Approved, Investigational |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Remoxipride is combined with Alphacetylmethadol. | Experimental, Illicit |
| Alprazolam | The risk or severity of adverse effects can be increased when Alprazolam is combined with Remoxipride. | Approved, Illicit, Investigational |
| Amiodarone | The metabolism of Remoxipride can be decreased when combined with Amiodarone. | Approved, Investigational |
| Amisulpride | The risk or severity of adverse effects can be increased when Remoxipride is combined with Amisulpride. | Approved, Investigational |
| Amitriptyline | The risk or severity of adverse effects can be increased when Remoxipride is combined with Amitriptyline. | Approved |
| Amobarbital | The risk or severity of adverse effects can be increased when Remoxipride is combined with Amobarbital. | Approved, Illicit |
| Amoxapine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Amoxapine. | Approved |
| Amperozide | The risk or severity of adverse effects can be increased when Remoxipride is combined with Amperozide. | Experimental |
| Amphetamine | Remoxipride may decrease the stimulatory activities of Amphetamine. | Approved, Illicit |
| Aripiprazole | The risk or severity of adverse effects can be increased when Remoxipride is combined with Aripiprazole. | Approved, Investigational |
| Artemether | The metabolism of Remoxipride can be decreased when combined with Artemether. | Approved |
| Articaine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Articaine. | Approved |
| Asenapine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Asenapine. | Approved |
| Atomoxetine | The metabolism of Remoxipride can be decreased when combined with Atomoxetine. | Approved |
| Azelastine | Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Azelastine. | Approved |
| Azelastine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Azelastine. | Approved |
| Baclofen | The risk or severity of adverse effects can be increased when Remoxipride is combined with Baclofen. | Approved |
| Barbital | The risk or severity of adverse effects can be increased when Remoxipride is combined with Barbital. | Illicit |
| Benperidol | The risk or severity of adverse effects can be increased when Remoxipride is combined with Benperidol. | Investigational |
| Benzocaine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Benzocaine. | Approved |
| Benzphetamine | Remoxipride may decrease the stimulatory activities of Benzphetamine. | Approved, Illicit |
| Benzyl alcohol | The risk or severity of adverse effects can be increased when Remoxipride is combined with Benzyl alcohol. | Approved |
| Betaxolol | The metabolism of Remoxipride can be decreased when combined with Betaxolol. | Approved |
| Brexpiprazole | The risk or severity of adverse effects can be increased when Remoxipride is combined with Brexpiprazole. | Approved |
| Brimonidine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Brimonidine. | Approved |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. | Approved |
| Bromazepam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Bromazepam. | Approved, Illicit |
| Bromocriptine | The risk or severity of adverse effects can be increased when Bromocriptine is combined with Remoxipride. | Approved, Investigational |
| Brompheniramine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Brompheniramine. | Approved |
| Brotizolam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Brotizolam. | Approved, Withdrawn |
| Bupivacaine | The risk or severity of adverse effects can be increased when Bupivacaine is combined with Remoxipride. | Approved, Investigational |
| Buprenorphine | Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. | Approved, Illicit, Investigational, Vet Approved |
| Bupropion | The metabolism of Remoxipride can be decreased when combined with Bupropion. | Approved |
| Buspirone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Buspirone. | Approved, Investigational |
| Butabarbital | The risk or severity of adverse effects can be increased when Butabarbital is combined with Remoxipride. | Approved, Illicit |
| Butalbital | The risk or severity of adverse effects can be increased when Remoxipride is combined with Butalbital. | Approved, Illicit |
| Butethal | The risk or severity of adverse effects can be increased when Remoxipride is combined with Butethal. | Approved, Illicit |
| Butorphanol | The risk or severity of adverse effects can be increased when Remoxipride is combined with Butorphanol. | Approved, Illicit, Vet Approved |
| Cabergoline | The risk or severity of adverse effects can be increased when Cabergoline is combined with Remoxipride. | Approved |
| Carbamazepine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Carbamazepine. | Approved, Investigational |
| Carbinoxamine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Carbinoxamine. | Approved |
| Carfentanil | The risk or severity of adverse effects can be increased when Remoxipride is combined with Carfentanil. | Illicit, Vet Approved |
| Carisoprodol | The risk or severity of adverse effects can be increased when Remoxipride is combined with Carisoprodol. | Approved |
| Celecoxib | The metabolism of Remoxipride can be decreased when combined with Celecoxib. | Approved, Investigational |
| Cetirizine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Cetirizine. | Approved |
| Chloral hydrate | The risk or severity of adverse effects can be increased when Remoxipride is combined with Chloral hydrate. | Approved, Illicit, Vet Approved |
| Chlordiazepoxide | The risk or severity of adverse effects can be increased when Remoxipride is combined with Chlordiazepoxide. | Approved, Illicit |
| Chlormezanone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Chlormezanone. | Approved, Withdrawn |
| Chloroprocaine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Chloroprocaine. | Approved |
| Chloroquine | The metabolism of Remoxipride can be decreased when combined with Chloroquine. | Approved, Vet Approved |
| Chlorphenamine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorphenamine. | Approved |
| Chlorphentermine | Remoxipride may decrease the stimulatory activities of Chlorphentermine. | Illicit, Withdrawn |
| Chlorpromazine | The metabolism of Remoxipride can be decreased when combined with Chlorpromazine. | Approved, Vet Approved |
| Chlorprothixene | The risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorprothixene. | Approved, Withdrawn |
| Chlorzoxazone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorzoxazone. | Approved |
| Cholecalciferol | The metabolism of Remoxipride can be decreased when combined with Cholecalciferol. | Approved, Nutraceutical |
| Cimetidine | The metabolism of Remoxipride can be decreased when combined with Cimetidine. | Approved |
| Cinacalcet | The metabolism of Remoxipride can be decreased when combined with Cinacalcet. | Approved |
| Cinchocaine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Cinchocaine. | Approved, Vet Approved |
| Citalopram | The metabolism of Remoxipride can be decreased when combined with Citalopram. | Approved |
| Clemastine | The metabolism of Remoxipride can be decreased when combined with Clemastine. | Approved |
| Clidinium | The risk or severity of adverse effects can be increased when Remoxipride is combined with Clidinium. | Approved |
| Clobazam | The metabolism of Remoxipride can be decreased when combined with Clobazam. | Approved, Illicit |
| Clomipramine | The metabolism of Remoxipride can be decreased when combined with Clomipramine. | Approved, Vet Approved |
| Clonazepam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Clonazepam. | Approved, Illicit |
| Clonidine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Clonidine. | Approved |
| Clorazepate | The risk or severity of adverse effects can be increased when Remoxipride is combined with Clorazepate. | Approved, Illicit |
| Clotrimazole | The metabolism of Remoxipride can be decreased when combined with Clotrimazole. | Approved, Vet Approved |
| Clozapine | The metabolism of Remoxipride can be decreased when combined with Clozapine. | Approved |
| Cobicistat | The serum concentration of Remoxipride can be increased when it is combined with Cobicistat. | Approved |
| Cocaine | The metabolism of Remoxipride can be decreased when combined with Cocaine. | Approved, Illicit |
| Codeine | The risk or severity of adverse effects can be increased when Codeine is combined with Remoxipride. | Approved, Illicit |
| Cyclizine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Cyclizine. | Approved |
| Cyclobenzaprine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Cyclobenzaprine. | Approved |
| Cyproheptadine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Cyproheptadine. | Approved |
| Dantrolene | The risk or severity of adverse effects can be increased when Remoxipride is combined with Dantrolene. | Approved |
| Dapiprazole | The risk or severity of adverse effects can be increased when Dapiprazole is combined with Remoxipride. | Approved |
| Dapoxetine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Dapoxetine. | Investigational |
| Darifenacin | The metabolism of Remoxipride can be decreased when combined with Darifenacin. | Approved, Investigational |
| Darunavir | The serum concentration of Remoxipride can be increased when it is combined with Darunavir. | Approved |
| Delavirdine | The metabolism of Remoxipride can be decreased when combined with Delavirdine. | Approved |
| Deramciclane | The risk or severity of adverse effects can be increased when Remoxipride is combined with deramciclane. | Investigational |
| Desflurane | The risk or severity of adverse effects can be increased when Remoxipride is combined with Desflurane. | Approved |
| Desipramine | The metabolism of Remoxipride can be decreased when combined with Desipramine. | Approved |
| Desloratadine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Desloratadine. | Approved, Investigational |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Remoxipride. | Approved |
| Dexbrompheniramine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Dexbrompheniramine. | Approved |
| Dexmedetomidine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Dexmedetomidine. | Approved, Vet Approved |
| Dextroamphetamine | Remoxipride may decrease the stimulatory activities of Dextroamphetamine. | Approved, Illicit |
| Dextromethorphan | The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Remoxipride. | Approved |
| Dextromoramide | The risk or severity of adverse effects can be increased when Remoxipride is combined with Dextromoramide. | Experimental, Illicit |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Remoxipride is combined with Dextropropoxyphene. | Approved, Illicit, Withdrawn |
| Dezocine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Dezocine. | Approved |
| Diazepam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Diazepam. | Approved, Illicit, Vet Approved |
| Diethylpropion | Remoxipride may decrease the stimulatory activities of Diethylpropion. | Approved, Illicit |
| Difenoxin | The risk or severity of adverse effects can be increased when Remoxipride is combined with Difenoxin. | Approved, Illicit |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydrocodeine. | Approved, Illicit |
| Dihydroergotamine | The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Remoxipride. | Approved |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydroetorphine. | Experimental, Illicit |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Dihydromorphine. | Experimental, Illicit |
| Dimenhydrinate | The risk or severity of adverse effects can be increased when Remoxipride is combined with Dimenhydrinate. | Approved |
| Diphenhydramine | The metabolism of Remoxipride can be decreased when combined with Diphenhydramine. | Approved |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Remoxipride is combined with Diphenoxylate. | Approved, Illicit |
| Doxepin | The risk or severity of adverse effects can be increased when Remoxipride is combined with Doxepin. | Approved |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. | Approved, Vet Approved |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. | Approved, Illicit |
| Dronedarone | The metabolism of Remoxipride can be decreased when combined with Dronedarone. | Approved |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. | Approved, Vet Approved |
| Drotebanol | The risk or severity of adverse effects can be increased when Remoxipride is combined with Drotebanol. | Experimental, Illicit |
| Duloxetine | The metabolism of Remoxipride can be decreased when combined with Duloxetine. | Approved |
| Dyclonine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Dyclonine. | Approved |
| Ecgonine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Ecgonine. | Experimental, Illicit |
| Ecopipam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Ecopipam. | Investigational |
| Efavirenz | The risk or severity of adverse effects can be increased when Remoxipride is combined with Efavirenz. | Approved, Investigational |
| Eletriptan | The risk or severity of adverse effects can be increased when Eletriptan is combined with Remoxipride. | Approved, Investigational |
| Eliglustat | The metabolism of Remoxipride can be decreased when combined with Eliglustat. | Approved |
| Eltanolone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Pregnanolone. | Investigational |
| Enflurane | The risk or severity of adverse effects can be increased when Enflurane is combined with Remoxipride. | Approved, Vet Approved |
| Entacapone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Entacapone. | Approved, Investigational |
| Ergoloid mesylate | The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Remoxipride. | Approved |
| Ergonovine | The risk or severity of adverse effects can be increased when Ergonovine is combined with Remoxipride. | Approved |
| Ergotamine | The risk or severity of adverse effects can be increased when Ergotamine is combined with Remoxipride. | Approved |
| Escitalopram | The risk or severity of adverse effects can be increased when Escitalopram is combined with Remoxipride. | Approved, Investigational |
| Estazolam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Estazolam. | Approved, Illicit |
| Eszopiclone | The risk or severity of adverse effects can be increased when Eszopiclone is combined with Remoxipride. | Approved |
| Ethanol | Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Ethanol. | Approved |
| Ethchlorvynol | The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remoxipride. | Approved, Illicit, Withdrawn |
| Ethosuximide | The risk or severity of adverse effects can be increased when Remoxipride is combined with Ethosuximide. | Approved |
| Ethotoin | The risk or severity of adverse effects can be increased when Remoxipride is combined with Ethotoin. | Approved |
| Ethyl carbamate | The risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl carbamate. | Withdrawn |
| Ethyl loflazepate | The risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl loflazepate. | Approved, Illicit |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Ethylmorphine. | Approved, Illicit |
| Etidocaine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Etidocaine. | Approved |
| Etifoxine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Etifoxine. | Withdrawn |
| Etizolam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Etizolam. | Approved |
| Etomidate | The risk or severity of adverse effects can be increased when Etomidate is combined with Remoxipride. | Approved |
| Etoperidone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Etoperidone. | Approved |
| Etorphine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Etorphine. | Illicit, Vet Approved |
| Ezogabine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Ezogabine. | Approved |
| Felbamate | The risk or severity of adverse effects can be increased when Remoxipride is combined with Felbamate. | Approved |
| Fencamfamine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Fencamfamine. | Approved, Illicit, Withdrawn |
| Fentanyl | The risk or severity of adverse effects can be increased when Remoxipride is combined with Fentanyl. | Approved, Illicit, Investigational, Vet Approved |
| Fexofenadine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Fexofenadine. | Approved |
| Flibanserin | The risk or severity of adverse effects can be increased when Remoxipride is combined with Flibanserin. | Approved |
| Fludiazepam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Fludiazepam. | Approved, Illicit |
| Flunarizine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Flunarizine. | Approved |
| Flunitrazepam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Flunitrazepam. | Approved, Illicit |
| Fluoxetine | The metabolism of Remoxipride can be decreased when combined with Fluoxetine. | Approved, Vet Approved |
| Flupentixol | The risk or severity of adverse effects can be increased when Remoxipride is combined with Flupentixol. | Approved, Withdrawn |
| Fluphenazine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Fluphenazine. | Approved |
| Flurazepam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Flurazepam. | Approved, Illicit |
| Fluspirilene | The risk or severity of adverse effects can be increased when Remoxipride is combined with Fluspirilene. | Approved |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Remoxipride is combined with Fluticasone Propionate. | Approved |
| Fluvoxamine | The metabolism of Remoxipride can be decreased when combined with Fluvoxamine. | Approved, Investigational |
| Fosphenytoin | The risk or severity of adverse effects can be increased when Remoxipride is combined with Fosphenytoin. | Approved |
| Fospropofol | The risk or severity of adverse effects can be increased when Remoxipride is combined with Fospropofol. | Approved, Illicit |
| Frovatriptan | The risk or severity of adverse effects can be increased when Frovatriptan is combined with Remoxipride. | Approved, Investigational |
| Gabapentin | The risk or severity of adverse effects can be increased when Remoxipride is combined with Gabapentin. | Approved, Investigational |
| Gabapentin Enacarbil | The risk or severity of adverse effects can be increased when Remoxipride is combined with gabapentin enacarbil. | Approved |
| Gamma Hydroxybutyric Acid | The risk or severity of adverse effects can be increased when Remoxipride is combined with Gamma Hydroxybutyric Acid. | Approved, Illicit |
| Gepirone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Gepirone. | Investigational |
| Glutethimide | The risk or severity of adverse effects can be increased when Remoxipride is combined with Glutethimide. | Approved, Illicit |
| Guanfacine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Guanfacine. | Approved, Investigational |
| Halazepam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Halazepam. | Approved, Illicit, Withdrawn |
| Haloperidol | The metabolism of Remoxipride can be decreased when combined with Haloperidol. | Approved |
| Halothane | The risk or severity of adverse effects can be increased when Remoxipride is combined with Halothane. | Approved, Vet Approved |
| Heroin | The risk or severity of adverse effects can be increased when Remoxipride is combined with Heroin. | Approved, Illicit |
| Hexobarbital | The risk or severity of adverse effects can be increased when Remoxipride is combined with Hexobarbital. | Approved |
| Hydrocodone | Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. | Approved, Illicit |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hydromorphone is combined with Remoxipride. | Approved, Illicit |
| Hydroxyamphetamine | Remoxipride may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide. | Approved |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. | Approved |
| Iloperidone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Iloperidone. | Approved |
| Imipramine | The metabolism of Remoxipride can be decreased when combined with Imipramine. | Approved |
| Indalpine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Indalpine. | Investigational, Withdrawn |
| Indinavir | The metabolism of Remoxipride can be decreased when combined with Indinavir. | Approved |
| Isocarboxazid | The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Remoxipride. | Approved |
| Isoflurane | The risk or severity of adverse effects can be increased when Remoxipride is combined with Isoflurane. | Approved, Vet Approved |
| Isoniazid | The metabolism of Remoxipride can be decreased when combined with Isoniazid. | Approved |
| Ketamine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Ketamine. | Approved, Vet Approved |
| Ketazolam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Ketazolam. | Approved |
| Ketobemidone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Ketobemidone. | Approved |
| Ketoconazole | The metabolism of Remoxipride can be decreased when combined with Ketoconazole. | Approved, Investigational |
| Lamotrigine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Lamotrigine. | Approved, Investigational |
| Levetiracetam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Levetiracetam. | Approved, Investigational |
| Levobupivacaine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Levobupivacaine. | Approved |
| Levocabastine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Levocabastine. | Approved |
| Levocetirizine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Levocetirizine. | Approved |
| Levodopa | The risk or severity of adverse effects can be increased when Remoxipride is combined with Levodopa. | Approved |
| Levomethadyl Acetate | The risk or severity of adverse effects can be increased when Remoxipride is combined with Levomethadyl Acetate. | Approved |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Remoxipride. | Approved |
| Levorphanol | The risk or severity of adverse effects can be increased when Remoxipride is combined with Levorphanol. | Approved |
| Lidocaine | The risk or severity of adverse effects can be increased when Lidocaine is combined with Remoxipride. | Approved, Vet Approved |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Remoxipride. | Approved, Investigational |
| Lisdexamfetamine | Remoxipride may decrease the stimulatory activities of Lisdexamfetamine. | Approved, Investigational |
| Lithium | Lithium may increase the neurotoxic activities of Remoxipride. | Approved |
| Lofentanil | The risk or severity of adverse effects can be increased when Remoxipride is combined with Lofentanil. | Illicit |
| Lopinavir | The metabolism of Remoxipride can be decreased when combined with Lopinavir. | Approved |
| Loratadine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Loratadine. | Approved |
| Lorazepam | The risk or severity of adverse effects can be increased when Lorazepam is combined with Remoxipride. | Approved |
| Lorcaserin | The metabolism of Remoxipride can be decreased when combined with Lorcaserin. | Approved |
| Loxapine | The risk or severity of adverse effects can be increased when Loxapine is combined with Remoxipride. | Approved |
| Lumefantrine | The metabolism of Remoxipride can be decreased when combined with Lumefantrine. | Approved |
| Lurasidone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Lurasidone. | Approved |
| Magnesium Sulfate | Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. | Approved, Vet Approved |
| Maprotiline | The risk or severity of adverse effects can be increased when Remoxipride is combined with Maprotiline. | Approved |
| Meclizine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Meclizine. | Approved |
| Melatonin | The risk or severity of adverse effects can be increased when Remoxipride is combined with Melatonin. | Approved, Nutraceutical, Vet Approved |
| Melperone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Melperone. | Approved |
| Mephedrone | Remoxipride may decrease the stimulatory activities of Mephedrone. | Investigational |
| Mephentermine | Remoxipride may decrease the stimulatory activities of Mephentermine. | Approved |
| Mepivacaine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Mepivacaine. | Approved, Vet Approved |
| Meprobamate | The risk or severity of adverse effects can be increased when Meprobamate is combined with Remoxipride. | Approved, Illicit |
| Mequitazine | Remoxipride may increase the arrhythmogenic activities of Mequitazine. | Approved |
| Mesoridazine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Mesoridazine. | Approved |
| Metaxalone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Metaxalone. | Approved |
| Methadone | The metabolism of Remoxipride can be decreased when combined with Methadone. | Approved |
| Methadyl Acetate | The risk or severity of adverse effects can be increased when Remoxipride is combined with Methadyl Acetate. | Approved, Illicit |
| Methamphetamine | Remoxipride may decrease the stimulatory activities of Methamphetamine. | Approved, Illicit |
| Methapyrilene | The risk or severity of adverse effects can be increased when Remoxipride is combined with Methapyrilene. | Withdrawn |
| Methaqualone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Methaqualone. | Illicit, Withdrawn |
| Methocarbamol | The risk or severity of adverse effects can be increased when Remoxipride is combined with Methocarbamol. | Approved, Vet Approved |
| Methohexital | The risk or severity of adverse effects can be increased when Remoxipride is combined with Methohexital. | Approved |
| Methotrimeprazine | Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. | Approved |
| Methoxyflurane | The risk or severity of adverse effects can be increased when Remoxipride is combined with Methoxyflurane. | Approved, Vet Approved |
| Methsuximide | The risk or severity of adverse effects can be increased when Remoxipride is combined with Methsuximide. | Approved |
| Methylecgonine | The risk or severity of adverse effects can be increased when Remoxipride is combined with ECGONINE METHYL ESTER. | Experimental |
| Methylphenidate | The risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenidate. | Approved, Investigational |
| Methylphenobarbital | The risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenobarbital. | Approved |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Remoxipride. | Approved, Investigational |
| Metoprolol | The metabolism of Remoxipride can be decreased when combined with Metoprolol. | Approved, Investigational |
| Metyrosine | Remoxipride may increase the sedative activities of Metyrosine. | Approved |
| Midazolam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Midazolam. | Approved, Illicit |
| Milnacipran | The risk or severity of adverse effects can be increased when Milnacipran is combined with Remoxipride. | Approved |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. | Approved, Investigational |
| Mirabegron | The metabolism of Remoxipride can be decreased when combined with Mirabegron. | Approved |
| Mirtazapine | Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. | Approved |
| MMDA | Remoxipride may decrease the stimulatory activities of MMDA. | Experimental, Illicit |
| Moclobemide | The risk or severity of adverse effects can be increased when Moclobemide is combined with Remoxipride. | Approved |
| Molindone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Molindone. | Approved |
| Morphine | The risk or severity of adverse effects can be increased when Morphine is combined with Remoxipride. | Approved, Investigational |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. | Approved, Investigational |
| Nalbuphine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Nalbuphine. | Approved |
| Naratriptan | The risk or severity of adverse effects can be increased when Naratriptan is combined with Remoxipride. | Approved, Investigational |
| Nefazodone | The risk or severity of adverse effects can be increased when Nefazodone is combined with Remoxipride. | Approved, Withdrawn |
| Nevirapine | The metabolism of Remoxipride can be decreased when combined with Nevirapine. | Approved |
| Nicardipine | The metabolism of Remoxipride can be decreased when combined with Nicardipine. | Approved |
| Nilotinib | The metabolism of Remoxipride can be decreased when combined with Nilotinib. | Approved, Investigational |
| Nitrazepam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Nitrazepam. | Approved |
| Nitrous oxide | The risk or severity of adverse effects can be increased when Remoxipride is combined with Nitrous oxide. | Approved, Vet Approved |
| Norflurane | The risk or severity of adverse effects can be increased when Remoxipride is combined with 1,1,1,2 Tetrafluoroethane. | Investigational |
| Normethadone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Normethadone. | Approved, Illicit |
| Nortriptyline | The risk or severity of adverse effects can be increased when Remoxipride is combined with Nortriptyline. | Approved |
| Olanzapine | The risk or severity of adverse effects can be increased when Olanzapine is combined with Remoxipride. | Approved, Investigational |
| Olopatadine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Olopatadine. | Approved |
| Ondansetron | The risk or severity of adverse effects can be increased when Remoxipride is combined with Ondansetron. | Approved |
| Opium | The risk or severity of adverse effects can be increased when Remoxipride is combined with Opium. | Approved, Illicit |
| Orphenadrine | Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. | Approved |
| Osanetant | The risk or severity of adverse effects can be increased when Remoxipride is combined with Osanetant. | Investigational |
| Oxazepam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Oxazepam. | Approved |
| Oxethazaine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Oxetacaine. | Investigational |
| Oxprenolol | The risk or severity of adverse effects can be increased when Remoxipride is combined with Oxprenolol. | Approved |
| Oxybuprocaine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Oxybuprocaine. | Approved |
| Oxycodone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Oxycodone. | Approved, Illicit, Investigational |
| Oxymorphone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Oxymorphone. | Approved, Investigational, Vet Approved |
| Paliperidone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Paliperidone. | Approved |
| Panobinostat | The serum concentration of Remoxipride can be increased when it is combined with Panobinostat. | Approved, Investigational |
| Paraldehyde | Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. | Approved |
| Paroxetine | The metabolism of Remoxipride can be decreased when combined with Paroxetine. | Approved, Investigational |
| Peginterferon alfa-2b | The serum concentration of Remoxipride can be decreased when it is combined with Peginterferon alfa-2b. | Approved |
| Pentazocine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Pentazocine. | Approved, Vet Approved |
| Pentobarbital | The risk or severity of adverse effects can be increased when Pentobarbital is combined with Remoxipride. | Approved, Vet Approved |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. | Approved |
| Perazine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Perazine. | Investigational |
| Perospirone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Perospirone. | Approved |
| Perphenazine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Perphenazine. | Approved |
| Pethidine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Pethidine. | Approved |
| Phenelzine | The risk or severity of adverse effects can be increased when Phenelzine is combined with Remoxipride. | Approved |
| Phenobarbital | The risk or severity of adverse effects can be increased when Remoxipride is combined with Phenobarbital. | Approved |
| Phentermine | Remoxipride may decrease the stimulatory activities of Phentermine. | Approved, Illicit |
| Phenytoin | The risk or severity of adverse effects can be increased when Remoxipride is combined with Phenytoin. | Approved, Vet Approved |
| Pimozide | The risk or severity of adverse effects can be increased when Remoxipride is combined with Pimozide. | Approved |
| Pipamperone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Pipamperone. | Approved |
| Pipotiazine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Pipotiazine. | Approved |
| Piritramide | The risk or severity of adverse effects can be increased when Remoxipride is combined with Piritramide. | Investigational |
| Pomalidomide | The risk or severity of adverse effects can be increased when Remoxipride is combined with Pomalidomide. | Approved |
| Pramipexole | Remoxipride may increase the sedative activities of Pramipexole. | Approved, Investigational |
| Pramocaine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Pramocaine. | Approved |
| Prazepam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Prazepam. | Approved, Illicit |
| Pregabalin | The risk or severity of adverse effects can be increased when Pregabalin is combined with Remoxipride. | Approved, Illicit, Investigational |
| Prilocaine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Prilocaine. | Approved |
| Primidone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Primidone. | Approved, Vet Approved |
| Procaine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Procaine. | Approved, Investigational, Vet Approved |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Remoxipride. | Approved |
| Prochlorperazine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Prochlorperazine. | Approved, Vet Approved |
| Promazine | The metabolism of Remoxipride can be decreased when combined with Promazine. | Approved, Vet Approved |
| Promethazine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Promethazine. | Approved |
| Proparacaine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Proparacaine. | Approved, Vet Approved |
| Propofol | The risk or severity of adverse effects can be increased when Remoxipride is combined with Propofol. | Approved, Investigational, Vet Approved |
| Propoxycaine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Propoxycaine. | Approved |
| Protriptyline | The risk or severity of adverse effects can be increased when Remoxipride is combined with Protriptyline. | Approved |
| Pseudoephedrine | Remoxipride may decrease the stimulatory activities of Pseudoephedrine. | Approved |
| Quazepam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Quazepam. | Approved, Illicit |
| Quetiapine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Quetiapine. | Approved |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Remoxipride. | Approved |
| Quinidine | The metabolism of Remoxipride can be decreased when combined with Quinidine. | Approved |
| Quinine | The metabolism of Remoxipride can be decreased when combined with Quinine. | Approved |
| Raclopride | The risk or severity of adverse effects can be increased when Remoxipride is combined with Raclopride. | Investigational |
| Ramelteon | The risk or severity of adverse effects can be increased when Remoxipride is combined with Ramelteon. | Approved, Investigational |
| Ranolazine | The metabolism of Remoxipride can be decreased when combined with Ranolazine. | Approved, Investigational |
| Rasagiline | The risk or severity of adverse effects can be increased when Rasagiline is combined with Remoxipride. | Approved |
| Remifentanil | The risk or severity of adverse effects can be increased when Remoxipride is combined with Remifentanil. | Approved |
| Reserpine | The risk or severity of adverse effects can be increased when Reserpine is combined with Remoxipride. | Approved |
| Risperidone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Risperidone. | Approved, Investigational |
| Ritanserin | The risk or severity of adverse effects can be increased when Remoxipride is combined with Ritanserin. | Investigational |
| Ritobegron | Remoxipride may decrease the stimulatory activities of Ritobegron. | Investigational |
| Ritonavir | The metabolism of Remoxipride can be decreased when combined with Ritonavir. | Approved, Investigational |
| Rizatriptan | The risk or severity of adverse effects can be increased when Rizatriptan is combined with Remoxipride. | Approved |
| Rolapitant | The metabolism of Remoxipride can be decreased when combined with Rolapitant. | Approved |
| Ropinirole | Remoxipride may increase the sedative activities of Ropinirole. | Approved, Investigational |
| Ropivacaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Remoxipride. | Approved |
| Rotigotine | Remoxipride may increase the sedative activities of Rotigotine. | Approved |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Remoxipride. | Approved |
| Scopolamine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Scopolamine. | Approved |
| Secobarbital | The risk or severity of adverse effects can be increased when Remoxipride is combined with Secobarbital. | Approved, Vet Approved |
| Selegiline | The risk or severity of adverse effects can be increased when Selegiline is combined with Remoxipride. | Approved, Investigational, Vet Approved |
| Sepranolone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Uc1010. | Investigational |
| Sertindole | The risk or severity of adverse effects can be increased when Remoxipride is combined with Sertindole. | Approved, Withdrawn |
| Sertraline | The metabolism of Remoxipride can be decreased when combined with Sertraline. | Approved |
| Sevoflurane | The risk or severity of adverse effects can be increased when Remoxipride is combined with Sevoflurane. | Approved, Vet Approved |
| Sodium oxybate | Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. | Approved |
| Stiripentol | The metabolism of Remoxipride can be decreased when combined with Stiripentol. | Approved |
| Sufentanil | The risk or severity of adverse effects can be increased when Remoxipride is combined with Sufentanil. | Approved, Investigational |
| Sulpiride | The risk or severity of adverse effects can be increased when Remoxipride is combined with Sulpiride. | Approved |
| Sumatriptan | The risk or severity of adverse effects can be increased when Sumatriptan is combined with Remoxipride. | Approved, Investigational |
| Suvorexant | Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. | Approved |
| Tandospirone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Tandospirone. | Investigational |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Remoxipride. | Approved |
| Tasimelteon | The risk or severity of adverse effects can be increased when Remoxipride is combined with Tasimelteon. | Approved |
| Tedizolid Phosphate | The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Remoxipride. | Approved |
| Temazepam | The risk or severity of adverse effects can be increased when Temazepam is combined with Remoxipride. | Approved |
| Terbinafine | The metabolism of Remoxipride can be decreased when combined with Terbinafine. | Approved, Investigational, Vet Approved |
| Tetrabenazine | The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Remoxipride. | Approved |
| Tetracaine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Tetracaine. | Approved, Vet Approved |
| Tetrodotoxin | The risk or severity of adverse effects can be increased when Remoxipride is combined with Tetrodotoxin. | Investigational |
| Thalidomide | Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. | Approved, Investigational, Withdrawn |
| Thiamylal | The risk or severity of adverse effects can be increased when Remoxipride is combined with Thiamylal. | Approved, Vet Approved |
| Thiopental | The risk or severity of adverse effects can be increased when Remoxipride is combined with Thiopental. | Approved, Vet Approved |
| Thioridazine | The metabolism of Remoxipride can be decreased when combined with Thioridazine. | Withdrawn |
| Thiothixene | The risk or severity of adverse effects can be increased when Remoxipride is combined with Thiothixene. | Approved |
| Tiagabine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Tiagabine. | Approved |
| Tiapride | The risk or severity of adverse effects can be increased when Remoxipride is combined with Tiapride. | Approved, Investigational |
| Ticlopidine | The metabolism of Remoxipride can be decreased when combined with Ticlopidine. | Approved |
| Tipranavir | The metabolism of Remoxipride can be decreased when combined with Tipranavir. | Approved, Investigational |
| Tizanidine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Tizanidine. | Approved |
| Tolcapone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Tolcapone. | Approved, Withdrawn |
| Topiramate | The risk or severity of adverse effects can be increased when Remoxipride is combined with Topiramate. | Approved |
| Tramadol | The risk or severity of adverse effects can be increased when Tramadol is combined with Remoxipride. | Approved, Investigational |
| Trans-2-Phenylcyclopropylamine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Trans-2-Phenylcyclopropylamine. | Experimental |
| Tranylcypromine | The metabolism of Remoxipride can be decreased when combined with Tranylcypromine. | Approved |
| Trazodone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Trazodone. | Approved, Investigational |
| Triazolam | The risk or severity of adverse effects can be increased when Remoxipride is combined with Triazolam. | Approved |
| Trifluoperazine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Trifluoperazine. | Approved |
| Triflupromazine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Triflupromazine. | Approved, Vet Approved |
| Trimipramine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Trimipramine. | Approved |
| Triprolidine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Triprolidine. | Approved |
| Valproic Acid | The risk or severity of adverse effects can be increased when Valproic Acid is combined with Remoxipride. | Approved, Investigational |
| Venlafaxine | The metabolism of Remoxipride can be decreased when combined with Venlafaxine. | Approved |
| Vigabatrin | The risk or severity of adverse effects can be increased when Remoxipride is combined with Vigabatrin. | Approved |
| Vilazodone | The risk or severity of adverse effects can be increased when Vilazodone is combined with Remoxipride. | Approved |
| Vortioxetine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Vortioxetine. | Approved |
| Zaleplon | The risk or severity of adverse effects can be increased when Remoxipride is combined with Zaleplon. | Approved, Illicit, Investigational |
| Ziconotide | The risk or severity of adverse effects can be increased when Remoxipride is combined with Ziconotide. | Approved |
| Zimelidine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Zimelidine. | Withdrawn |
| Ziprasidone | The metabolism of Remoxipride can be decreased when combined with Ziprasidone. | Approved |
| Zolmitriptan | The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Remoxipride. | Approved, Investigational |
| Zolpidem | Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. | Approved |
| Zonisamide | The risk or severity of adverse effects can be increased when Remoxipride is combined with Zonisamide. | Approved, Investigational |
| Zopiclone | The risk or severity of adverse effects can be increased when Remoxipride is combined with Zopiclone. | Approved |
| Zotepine | The risk or severity of adverse effects can be increased when Remoxipride is combined with Zotepine. | Approved |
| Zuclopenthixol | The risk or severity of adverse effects can be increased when Remoxipride is combined with Zuclopenthixol. | Approved, Investigational |
